Changes in Postmenopausal Hormone Replacement Therapy Use Among Women With High Cardiovascular Risk

2009/10/16 by Angela Ting‐Wei Hsu, Andrea Card, Susan Lin +3 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Menopause: Health Impacts and Treatments #Estrogen and related hormone effects #Hormonal and reproductive studies #Medicine #Hormone replacement therapy (female-to-male) #Postmenopausal women #Randomized controlled trial #Menopause #Internal medicine #Hormone therapy #Estrogen replacement therapy #Gynecology #Breast cancer #Cancer

paper · doi:10.2105/ajph.2009.159889

openalex publication_date 2009/10/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22

Abstract

After randomized trials failed to support the use of hormone replacement therapy (HRT) for preventing cardiovascular disease (CVD), HRT use for postmenopausal women declined. Our analysis of 1999-2000 and 2003-2004 National Health and Nutrition Surveys (NHANES) shows that HRT use decreased 19% (from 27.6 to 8.4%; P<.001) among women with CVD versus 3% (from 19.8 to 16.8%; P=.68) among low-risk women, suggesting that most of the drop in HRT use may be among women prescribed HRT as an unproven treatment to prevent CVD.

Citations

• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial

Cited by

• Randomized controlled trial [wikipedia]

Related

• A Sustained Decline in Postmenopausal Hormone Use
• Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations
• Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial
• Factors Associated With Hormone Replacement Therapy Use: A Systematic Review and Meta‐Analysis
• A rationale for PDE5 inhibitors as a cardiovascular risk mitigation strategy in postmenopausal women